World-First Immunotherapy Trial To Treat Type 1 Diabetes
Researchers at The University of Queensland have dosed 5 participants in the first clinical trial of a potentially revolutionary immunotherapy drug to treat Type 1 diabetes.
Professor Ranjeny Thomas AM from UQ's Frazer Institute has led the development of a targeted immunotherapy drug, ASITI-201, which has been designed to rebalance the body's immune response to protect insulin-producing pancreatic cells.
'In people with Type 1 diabetes, the immune system starts to recognise pancreatic cells as something it needs to attack, and right now the only available treatment is insulin replacement,' Professor Thomas said.
'We've taken a new approach and developed ASITI-201 using a protein from the pancreas, along with vitamin D to calm the immune response.
'This potential treatment uses the immune system's ability to heal and has been successful in controlling the disease in mice.'
Lead investigator Dr Aakansha Zala said the drug candidate aims to preserve as much pancreatic function for as long as possible in people recently diagnosed with Type 1 diabetes, to reduce the amount of insulin they need to administer.
'We are looking for people over the age of 18 who have been diagnosed with Type 1 diabetes within the last 5 years, to participate in the trial at the Translational Research Institute's Clinical Research Facility based at Brisbane's Princess Alexandra Hospital,' Dr Zala said.
'We will be looking at whether the drug changes the immune system in the way that we anticipate.'
Type 1 diabetes affects more than 120,000 Australians and usually develops in children and young adults.
'Ultimately, we need to move to larger trials which include children, who have a much faster progression to insulin dependence,' Professor Thomas said.
'We've been developing a similar drug with the potential to treat Rheumatoid Arthritis, and that knowledge has supported our development of this drug for Type 1 diabetes.'
The trial itself is being funded by the Medical Research Future Fund via Australia's national biotech incubator CUREator which helped form spin-out company Liperate Therapeutics – which was established by UQ's commercialisation company UniQuest.
The drug's preclinical proof of concept was supported by multiple grants from Breakthrough T1D (formerly JDRF) totalling $2.54 million between 2003-2015.
The Leona M. and Harry B. Helmsley Charitable Trust subsequently awarded two grants totalling $5.33 million to complete the preclinical development of the drug candidate, including safety studies and manufacturing.
Dr Ben Williams, Program Officer at Helmsley Charitable Trust, said the organisation is proud to have supported the research which is a step towards improving the lives of people with Type 1 diabetes.
'Bringing drug candidates from the laboratory into clinical testing is always a herculean effort,' Dr Williams said.
The Helmsley Charitable Trust is the largest private funder dedicated to transforming the trajectory of Type 1 diabetes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
16 minutes ago
- Scoop
Australia's Anti-Smoking Push Fuels Crime, Fails To Curb Smoking
The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) today condemned Australia's tobacco control strategy as a 'public health failure' that prioritises ideology over evidence, fuelling a A$6.3 billion illicit tobacco market while adult smoking rates remain stagnant. New data reveals one in four cigarettes consumed in Australia originates from the black market — a direct consequence of the world's highest tobacco taxes and restrictive vaping policies. CAPHRA argues this crisis exposes the fatal flaw in Australia's approach: prohibition without offering safer alternatives drives consumers to criminal networks rather than reducing harm. 'Australia's tobacco policy doesn't pass the pub test. Sky-high cigarette prices haven't made people quit—they've made criminals rich,' said Nancy Loucas, CAPHRA Executive Coordinator. 'The government's own figures show smoking rates flatlined at 11% since 2019 despite taxing a pack to A$50. Meanwhile, organised crime syndicates pocket A$2.3 billion annually in evaded excise, funding drug trafficking and violent turf wars.' Australia's illicit tobacco trade has surged by 46% since 2020, with over 800,000 smuggled cigarettes intercepted monthly at airports. Criminal syndicates increasingly exploit international travellers, while fire bombings of non-compliant retailers exceed 220 incidents since 2023. 'This isn't just about lost tax revenue—it's about community safety,' Loucas noted. 'Melbourne's 'tobacco war' has seen shops torched and innocent bystanders endangered. The government transformed a health issue into a national security crisis by ignoring basic economics: punitive taxes without alternatives breed black markets.' Compounding the issue, Australia's harsh vaping restrictions have pushed nicotine consumers toward unregulated products. Despite prescription-only access, 1.5 million Australians vape daily—87% sourcing devices illegally. CAPHRA contrasts Australia's approach with New Zealand, which halved smoking rates to 6% by legalising vaping and rejecting generational bans. 'New Zealand taxed tobacco heavily but gave smokers a ladder to climb down: affordable, regulated vapes. Australia took away the ladder and wondered why people kept smoking,' said Loucas. Pippa Starr, Director of Australia's ALIVE Advocacy Movement, added: 'The evidence is unequivocal: illicit trade has doubled since 2020, vaping restrictions fuel a A$2.3 billion black market, and smoking rates haven't budged. This isn't harm reduction—it's a policy failure that sacrifices public health for moral posturing.' 'Australia's strategy is a moralistic crusade, not public health. It's time to abandon prohibitionist dogma before more lives are lost to crime and complacency,'
Otago Daily Times
an hour ago
- Otago Daily Times
E-book allows replicas to be 3-D printed
Forget your yellow rubber ducky — what about a plesiosaur to play with in the bathtub? Fossilised bones from the prehistoric marine reptile are on display at the University of Otago's geology department and are among 50 fossils highlighted in a newly released e-book titled Fossil Treasures of the Geology Museum. Many of the fossils in the online book have logos that say "print ready", which means readers can click on it and print their own 3-D replica of the fossil. The book is the brainchild of University of Otago geology emeritus professor Daphne Lee, Geology Museum fossil collections archivist Dr Jeffrey Robinson, and University of Auckland School of Biological Sciences honorary academic and University of Otago visiting academic Dr Daniel Thomas. Dr Thomas said the e-book, released last week, brought to life the stories of a selection of the 60,000 fossil vertebrate, invertebrate and plant specimens held in the Geology Museum. Collected over 150 years of paleontology research at Otago, the fossils are used for research, teaching and outreach, and collectively represented the past 500 million years of Earth's evolutionary history, he said. Fossil Treasures of the Geology Museum tells the tale of around 50 of the specimens in the geology museum. "We have a range of materials like giant plesiosaurs; we have mega-sharks through to tiny little beetles, — so there's a huge diversity. "These are from locations including Foulden Maar, and much of our material is from Southland in particular, but also North Otago, South Canterbury and beyond. "So it has a strong southern, South Island focus." He said the 3-D models spanned the past 500 million years, which gave insight into the range of fossils at the museum. "Just as much as we have biological diversity represented in the book, we've actually got time diversity as well." Dr Thomas said the e-book was released last week and was free to access. It would be particularly useful for schools to use. "Our target age is 13-14 and slightly younger. "We actually have a couple of NCEA assessment standards that we had in mind while writing this. "Because this is an e-book, we have infinite capacity to make improvements, so what we really want is to hear back from people, especially teachers, who may be thinking, 'I could use this, but it's not quite there'. "We would really welcome those conversations so we can make improvements, to make this as useful and accessible as possible." He said the trio would continue to add to the resource in the future. "Certainly, those readers who are familiar with the collections will straight away see that there's a lot of material from the museum that's not currently in the e-book, especially plant material. "And, so, these are all chapters that are actually in the works right now, and this will just be added to over time."
RNZ News
29-05-2025
- RNZ News
Study finds link between low Vitamin D in babies
Babies born with low vitamin D levels are more likely to develop mental disorders like ADHD, schizophrenia, and autism later in life, according to a new study from the University of Queensland. Researchers analysed data from over 71,000 people, many of whom had a mental health disorder diagnosed during childhood and early adulthood. Professor John McGrath from UQ's Queensland Brain Institute led the study and says they found evidence that people with lower vitamin D concentration as a baby had an increased risk of schizophrenia, ASD and ADHD. To embed this content on your own webpage, cut and paste the following: See terms of use.
